Vapotherm (VAPO) PT Raised to $27.00 at Canaccord Genuity

Vapotherm (NYSE:VAPO) had its price target lifted by Canaccord Genuity from $22.00 to $27.00 in a research report sent to investors on Wednesday, The Fly reports. They currently have a buy rating on the stock.

A number of other brokerages also recently commented on VAPO. William Blair reiterated an outperform rating on shares of Vapotherm in a report on Monday, December 10th. Bank of America initiated coverage on shares of Vapotherm in a report on Monday, December 10th. They set a buy rating and a $26.00 price target for the company. Finally, BTIG Research initiated coverage on shares of Vapotherm in a report on Monday, December 10th. They set a buy rating for the company. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $26.50.

Shares of VAPO opened at $20.00 on Wednesday. The stock has a market cap of $334.64 million and a price-to-earnings ratio of -1.45. Vapotherm has a 12-month low of $14.70 and a 12-month high of $22.07.

Vapotherm (NYSE:VAPO) last announced its earnings results on Tuesday, March 12th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.12. The business had revenue of $11.69 million for the quarter, compared to analyst estimates of $11.00 million. Equities analysts expect that Vapotherm will post -2.7 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Arnhold LLC purchased a new stake in shares of Vapotherm during the fourth quarter worth about $227,000. Dean Capital Investments Management LLC purchased a new stake in shares of Vapotherm during the fourth quarter worth about $748,000. Bank of New York Mellon Corp purchased a new stake in shares of Vapotherm during the fourth quarter worth about $346,000. Perceptive Advisors LLC purchased a new stake in shares of Vapotherm during the fourth quarter worth about $24,464,000. Finally, Pura Vida Investments LLC purchased a new stake in shares of Vapotherm during the fourth quarter worth about $2,984,000. Institutional investors and hedge funds own 47.51% of the company’s stock.

Vapotherm Company Profile

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

Read More: Dividend

The Fly

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply